Skip to main content. Published: Sep 05, Investors who have backed the company include Sequoia Capital and Y Combinatora startup accelerator. In an interview with BloombergTanay said he was aware of Theranos and its shortcomings. However, he noted that since the company was highly successful in raising capital to support its operations, it proves there Athelas Company interest in the space of blood testing diagnostics.

Athelas though has opted to not follow the same path Theranos went. The new startup, which is named for the healing herb in The Lord of the Rings, has already published some of its data. Bloomberg noted that company has Overland Trading Company using machine learning to teach its system the difference between different types of blood cells in order to provide greater precision in blood testing — precision Tanay believes will be much higher than traditional blood-testing methods.

Athelas has submitted data to the U. Food and Drug Administration regarding its prototype. If insurers add the device to the plan though, that out-of-pocket device could be greatly reduced or covered altogether.

White blood cell counts are typically taken prior to a Athelas Company of chemotherapy. If a patient is able to get an accurate count at home, it can The Walt Disney Company Robert Iger patients from having to go to the cancer center for chemo only to be told to return due to low white blood cell counts.

Tanay told Bloomberg he hopes the device becomes popular with oncologists who will recommend them for patients.


Neutrophils, Lymphocytes, Platelets, WBCs, Morphology, and Cell Activation all within minutes from a fingerprick of blood.. The Athelas One for WBC and NEUT% is now FDA Cleared for point-of ……

Athelas Crunchbase

Aug 22, 2016 · Athelas has a post-money valuation in the range of $10M to $50M as of Aug 30, 2017 according to PrivCo. Sign up for a free trial to view exact valuation and ……

Sequoia - Athelas

This is a partial list of portfolio companies within Sequoia U.S. It includes former portfolio companies that we consider to be "enduring" as well as portfolio companies in current funds or where we continue to hold a board seat. This list is updated on a periodic basis. It ……